Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

Discovery of First-in-Class Calreticulin-targeted Degrader Antibody Conjugates Delivering a CDK9 Degrader Payload for the Treatment of CALR-mutated MPNs

Saturday, December 6, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the discovery of a novel therapy targeting calreticulin for treating CALR-mutated myeloproliferative neoplasms (MPNs). This first-in-class calreticulin-targeted degrader antibody conjugate delivers a CDK9 degrader payload, potentially enhancing treatment efficacy. The innovative approach may lead to significant advancements in managing these conditions.
Price reaction · baseline $1.46 (2025-12-05 close) · 1 other PRLD headline(s) in the window, move may be shared
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of a first-in-class therapy for CALR-mutated MPNs.
  • Potential for improved treatment outcomes with CDK9 degrader payload.
  • Innovative approach using calreticulin-targeted degrader antibody conjugates.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

Norman Fultang 1 , Ashley Schwab 1 , Sharayu Chandratre 1 , Jake Karwoski 1 , Grace Davis 1 , Ian Johnson 1 , Neha Bhagwat 1 , Yue Zou 1 , Arpita Mondal 1 , Max Foroutan 1 , Min Wang 1 , Andrew Buesking 1 , Chun Chen 1 , Corey Basch 1 , Ryan Holmes 1 , Sang Hyun Lee 1 , Diane Heiser 1 , Andrew Combs 1 , Peggy Scherle 1

Frequently Asked Questions

What is the significance of calreticulin-targeted therapy?

Calreticulin-targeted therapy represents a novel approach for treating CALR-mutated myeloproliferative neoplasms.

What is the role of the CDK9 degrader payload?

The CDK9 degrader payload aims to enhance treatment efficacy for CALR-mutated MPNs.

What type of cancer does this therapy target?

This therapy targets myeloproliferative neoplasms (MPNs) with CALR mutations.

Is this therapy first-in-class?

Yes, it is a first-in-class calreticulin-targeted degrader antibody conjugate.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare CALR-mutated MPNs CDK9 degrader antibody conjugates first-in-class therapy biopharma
Last updated: Dec 6, 2025

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →